Decreasing smoking behaviour and risk through CYP2A6 inhibition

Drug Discovery Today

Volumn 8, Issue 11, 2003, Pages 487-493

  Sellers, Edward M ^a   Tyndale, Rachel F ^b   Fernandes, Leona C ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c Ventana Clinical Research Corporation   (Canada)

Author keywords

Biochemistry; CYP2A6; Drug Development; Drug Discovery; Genetic; Molecular Medicine; Nicotine; Pharmaceutical Science; Pharmacology; Smoking; Treatment

Indexed keywords

CARCINOGEN; CYTOCHROME P450 2A6; NICOTINE;

CANCER; CIGARETTE SMOKING; ENZYME ACTIVITY; ENZYME INHIBITION; GENETIC MANIPULATION; HUMAN; NICOTINE REPLACEMENT THERAPY; PROTEIN POLYMORPHISM; REDUCTION; REGULATORY MECHANISM; REVIEW; RISK FACTOR; SMOKING; TOBACCO DEPENDENCE; TREATMENT OUTCOME;

ARYL HYDROCARBON HYDROXYLASES; HUMANS; METHOXSALEN; MIXED FUNCTION OXYGENASES; NICOTINE; POLYMORPHISM, GENETIC; PREVALENCE; TOBACCO USE DISORDER;

EID: 0038010210     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(03)02704-1     Document Type: Review

References (59)

1. The World Health Report 2002. 2002;World Health Organization.
2. Proctor R.N. Tobacco and the global lung cancer epidemic. Nat. Rev. Cancer. 1:2001;82-86.
3. Doll R., Peto R. The Causes of Cancer 1220. 1994;Oxford University Press.
4. Parkin D.M., et al. At least one in seven cases of cancer is caused by smoking. Global estimates for 1985. Int. J. Cancer. 59:1994;494-504.
5. Kuper H., et al. Tobacco use, cancer causation and public health impact. J. Intern. Med. 251:2002;455-466.
6. Shields P.G. Molecular epidemiology of smoking and lung cancer. Oncogene. 21:2002;6870-6876.
7. Hecht S.S. Cigarette smoking and lung cancer: chemical mechanisms and approaches to prevention. Lancet Oncol. 3:2002;461-469.
8. Hoffmann D., et al. The less harmful cigarette: a controversial issue. A tribute to Ernst L. Wynder. Chem. Res. Toxicol. 14:2001;767-790.
9. Twombly R. World Health Organization takes on 'tobacco epidemic'. J. Natl. Cancer Inst. 94:2002;644-646.
10. Leistikow B.N. The human and financial costs of smoking. Clin. Chest Med. 21:2000;189-197.
11. Henningfield J.E., Keenan R.M. Nicotine delivery kinetics and abuse liability. J. Consult. Clin. Psychol. 61:1993;743-750.
12. True W.R., et al. Genetic and environmental contributions to smoking. Addiction. 92:1997;1277-1287.
13. Madden P.A., et al. The genetics of smoking persistence in men and women: a multicultural study. Behav. Genet. 29:1999;383-393.
14. Benowitz N.L. Drug therapy: pharmacologic aspects of cigarette smoking and nicotine addition. N. Engl. J. Med. 319:1988;1318-1330.
15. Scherer G. Smoking behavior and compensation: a review of the literature. Psychopharmacology (Berl.). 145:1999;1-20.
16. Russell M.A., Feyerabend C. Cigarette smoking: a dependence on high-nicotine boli. Drug Metab. Rev. 8:1978;29-57.
17. Henningfield J.E., Goldberg S.R. Pharmacologic determinants of tobacco self-administration by humans. Pharmacol. Biochem. Behav. 30:1988;221-226.
18. Benowitz N.L. Cigarette smoking and nicotine addiction. Med. Clin. North Am. 76:1992;415-437.
19. Tomkins D.M., Sellers E.M. Addiction and the brain: the role of neurotransmitters in the cause and treatment of drug dependence. C.M.A.J. 164:2001;817-821.
20. Benowitz N.L., et al. Smokers of low yield cigarettes do not consume less nicotine. N. Engl. J. Med. 309:1983;139-142.
21. Svensson C.K. Clinical pharmacokinetics of nicotine. Clin. Pharmacokinet. 12:1987;30-40.
22. Pickworth W.B., et al. Transdermal nicotine: reduction of smoking with minimal abuse liability. Psychophamacology (Berl.). 115:1994;9-14.
23. Hurt R.D., et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N. Engl. J. Med. 337:1997;1195-1202.
24. Hays J.T., Ebbert J.O. Bupropion for the treatment of tobacco dependence: guidelines for balancing risks and benefits. CNS Drugs. 17:2003;71-83.
25. Peto R., et al. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ. 321:2000;323-329.
26. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). 1994;American Psychiatric Association, Washington, DC.
27. Benowitz N.L., et al. Determinants of nicotine intake while chewing nicotine polacrilex gum. Clin. Pharmacol. Ther. 41:1987;467-473.
28. Benowitz N.L., et al. Stable isotope method for studying transdermal drug absorption: the nicotine patch. Clin. Pharmacol. Ther. 50:1991;286-293.
29. Gupta S.K., et al. Single- and multiple-dose pharmacokinetics of Nicoderm® (nicotine transdermal system). J. Clin. Pharmacol. 33:1993;169-174.
30. Bannon Y.B., et al. Transdermal delivery of nicotine in normal human volunteers: a single dose and multiple dose study. Eur. J. Clin. Pharmacol. 37:1989;285-290.
31. Hurt R.D., et al. Serum nicotine and cotinine levels during nicotine-patch therapy. Clin. Pharmacol. Ther. 54:1993;98-106.
32. Messina E.S., et al. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J. Pharmacol. Exp. Ther. 282:1997;1608-1614.
33. Xu C., et al. CYP2A6 genetic variation and potential consequences. Adv. Drug Deliv. Rev. 54:2002;1245-1256.
34. Xu C., et al. An in vivo pilot study characterizing the new CYP2A6*7, *8 and *10 alleles. Biochem. Biophys. Res. Commun. 290:2002;318-324.
35. th Intl. Symp. Microsomes and Drug Oxidation, Sapporo, Japan 2002.
36. Raunio H., et al. Polymorphisms of CYP2A6 and its practical consequences. Br. J. Clin. Pharmacol. 52:2001;357-363.
37. Benowitz N.L., et al. Ethnic differences in n-glucuronidation of nicotine and cotinine. J. Pharmacol. Exp. Ther. 291:1999;1196-1203.
38. Perez-Stable E.J., et al. Nicotine metabolism and intake in black and white smokers. JAMA. 280:1998;152-156.
39. Kwon J.T., et al. Nicotine metabolism and CYP2A6 allele frequencies in Koreans. Pharmacogenetics. 11:2001;317-323.
40. Pianezza M.L., et al. Nicotine metabolism defect reduces smoking. Nature. 393:1998;750.
41. Fernandez-Salguero P., et al. A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. Am. J. Hum. Genet. 57:1995;651-660.
42. Gu D.F., et al. The use of long PCR to confirm three common alleles at the CYP2A6 locus and the relationship between genotype and smoking habit. Ann. Hum. Genet. 64:2000;383-390.
43. Rao Y., et al. Duplications and defects in the CYP2A6 gene: identification, genotyping and in vivo effects on smoking. Mol. Pharmacol. 58:2000;747-755.
44. Hecht S.S. Tobacco smoke carcinogens and lung cancer. J. Natl. Cancer Inst. 91:1999;1194-1210.
45. Crespi C.L., et al. Human cytochrome P450IIA3: cDNA sequence, role of the enzyme in the metabolic activation of promutagens, comparison to nitrosamine activation by human cytochrome P450IIE1. Carcinogenesis. 11:1990;1293-1300.
46. Yamazaki H., et al. Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis. 13:1992;1789-1794.
47. Patten C.J., et al. Evidence for cytochrome P450 2A6 and 3A4 as major catalysts for N'-nitrosonornicotine alpha-hydroxylation by human liver microsomes. Carcinogenesis. 18:1997;1623-1630.
48. Law M.R., et al. The dose-response relationship between cigarette consumption, biochemical markers and risk of lung cancer. Br. J. Cancer. 75:1997;1690-1693.
49. Benowitz N.L., et al. Stable isotope studies of nicotine kinetics and bioavailability. Clin. Pharmacol. Ther. 49:1991;270-277.
50. Sellers E.M., et al. Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking. Clin. Pharmacol. Ther. 68:2000;35-43.
51. Zhang W., et al. Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro. Drug Metab. Dispos. 29:2001;897-902.
52. Tyndale R.F., Sellers E.M. Variable CYP2A6-mediated metabolism alters smoking behaviour and risk. Drug Metab. Dispos. 29:2001;548-552.
53. Warner K.E. Cost effectiveness of smoking-cessation therapies. Interpretation of the evidence and implications for coverage. Pharmacoeconomics. 11:1997;538-549.
54. Klech H.H. Reduced smoking - an acceptable goal for the hopeless heavy smoker? Eur. Respir. J. 11:1998;263-264.
55. Benowitz N.L., et al. Sources of variability in nicotine and cotinine levels with use of nicotine nasal spray, transdermal nicotine, and cigarette smoking. Br. J. Clin. Pharmacol. 43:1997;259-267.
56. Sellers, E.M. et al. The effect of methoxsalen on nicotine and 4-(methylnitrosamino)-(3-pyridyl)-1-butanone (NNK) metabolism in vivo. Nicotine Tob. Res (in press).
57. Nameth-Coslett R., et al. Nicotine gum: dose-related effects on cigarette smoking and subjective ratings. Psychopharmacology (Berl.). 92:1987;424-430.
58. Pickworth W.B., et al. Effects of transdermal nicotine delivery on measures of acute nicotine withdrawal. J. Pharmacol. Exp. Ther. 279:1996;450-456.
59. Nemeth Coslett R., Henningfield J.E. Effects of nicotine chewing gum on cigarette smoking and subjective and physiologic effects. Clin. Pharmacol. Ther. 39:1986;625-630.